Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS, Biocon Team Up To Rekindle Oral Insulin Hopes

This article was originally published in PharmAsia News

Executive Summary

After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”


Related Content

Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission
India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner
Biocon's Oral Insulin Fails To Meet Primary Endpoint; Unfazed, Company Says Stage Set For Partnering Talks With Global Pharma
Bristol-Myers Squibb Plans To Make India Its Global Pharma Innovation Hub
Amylin, India's Biocon Join Hands For Peptide-Based Diabetes Compound


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts